Analysis of Interwoven Nitinol Stenting for the Treatment of Critical Limb Ischemia: Outcomes From an Average 3-Year Follow-up Period. (May 2022)

• Record Type: Journal Article
• Authors: Krishnan, Prakash; Tarricone, Arthur; Gee, Allen; Farhan, Serdar; Kamran, Haroon; Kapur, Vishal; Gujja, Karthik; Kini, Annapoorna; Sharma, Samin
• Is Part Of: Angiology. Volume 73:Number 5(2022)
• Page Start: 407
• Page End: 412
• Publication Date: 2022-05
• Subjects: Supera stent -- critical limb-threatening ischemia -- peripheral artery disease -- atherectomy -- percutaneous transluminal angioplasty -- lower extremity; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/00033197211043406
• Languages: English
• ISSNs: 0003-3197

Abstract

We assessed the clinical outcomes of patients with critical limb-threatening ischemia (CLTI) who underwent interwoven nitinol stent (Supera) implantation for significant stenoses of the femoropopliteal segment. In this retrospective cohort study, 116 consecutive patients with CLTI who were treated with Supera stents between September 2015 and March 2020 were included in this analysis. Primary endpoint analysis was completed for amputation-free survival, target lesion revascularization (TLR), and mortality. After a mean follow-up time of 3.4 years, 21 (18%) patients had undergone amputations, 3 (2.6%) died, and, overall, the amputation-free survival rate was 81%. TLR occurred in 21 (18%) patients, resulting in the freedom from target lesion revascularization of 82%. The average Wagner score for all patients was 2.8 ± 1.1. A subgroup analysis of 57 patients revealed a median ulcer size of 3.0 cm 2 [1.65, 9.0], with complete healing for 45 patients by 20 months. The Wagner score of this subgroup decreased by an average of 3.4 ± .9 points. Supera stents can be used together with other endovascular therapies and are a safe and effective treatment modality for CLTI.